WGS Overview

GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.

Wall Street analysts forecast WGS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WGS is171.43 USD with a low forecast of 155.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

GeneDx Holdings Corp revenue for the last quarter amounts to 120.99M USD, increased 26.50

GeneDx Holdings Corp. EPS for the last quarter amounts to -0.61 USD, decreased -405.00

GeneDx Holdings Corp (WGS) has 1300 emplpoyees as of March 11 2026.

Today WGS has the market capitalization of 2.60B USD.